Li Liu, MD
Ultima Vez Modificado: 1 de noviembre del 2001
Dear OncoLink "Ask the Experts,"
Would you please clarify the details of the latest treatment options for mucoepidermoid carcinoma of the parotid gland? The patient in question is a female of 35 years of age. Her disease is grade I and recurrent in nature. Also, could you please clarify the role of selective radiotherapy in this case.
Li Liu, MD, OncoLink Editorial Assistant, responds:
Dear Dr. MP,
Thank you for your question and interest.
Mucoepidermoid carcinoma has a broad spectrum of aggressiveness, from low grade tumors that primarily cause local problems to high grade tumors that unfortunately can have a very low survival rate. The most important prognosticators are age, tumor size and histology (high mitotic figures, neural involvement, necrosis, and anaplasia).
The indications for radiation therapy for mucoepidermoid carcinoma of the parotid are:
In addition to external beam radiation alone, intraoperative brachytherapy plus postoperative external beam radiation is also used to improve local control. A consultation from a radiation oncologist is warranted in this case.Imprima English
May 18, 2010 - Patients who are definitively treated within a year of diagnosis for papillary thyroid cancer that is limited to the thyroid gland have survival rates that are comparable to those who do not receive definitive treatment, according to a study reported in the May issue of the Archives of Otolaryngology -- Head & Neck Surgery.
May 18, 2010
Jun 17, 2011